Publications

Historical Article
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review
Ppublish 148 citations
Electronic publication date
January 5, 2022

View on Pubmed.gov 34506734 | View on doi.org 10.1016/S1473-3...

100 years of Mycobacterium bovis bacille Calmette-Guérin.

Search for publications in this journal Lancet Infect Dis - 22(1):e2-e12

Abstract

Mycobacterium bovis bacille Calmette-Guérin (BCG), an experimental vaccine designed to protect cattle from bovine tuberculosis, was administered for the first time to a newborn baby in Paris in 1921. Over the past century, BCG has saved tens of millions of lives and has been given to more humans than any other vaccine. It remains the sole tuberculosis vaccine licensed for use in humans. BCG provides long-lasting strong protection against miliary and meningeal tuberculosis in children, but it is less effective for the prevention of pulmonary tuberculosis, especially in adults. Evidence mainly from the past two decades suggests that BCG has non-specific benefits against non-tuberculous infections in newborn babies and in older adults, and offers immunotherapeutic benefit in certain malignancies such as non-muscle invasive bladder cancer. However, as a live attenuated vaccine, BCG can cause localised or disseminated infections in immunocompromised hosts, which can also occur following intravesical installation of BCG for the treatment of bladder cancer. The legacy of BCG includes fundamental discoveries about tuberculosis-specific and non-specific immunity and the demonstration that tuberculosis is a vaccine-preventable disease, providing a foundation for new vaccines to hasten tuberculosis elimination.

References

Am J Public Health Nations Health. 1928 Jul;18(7):843-64

Clin Infect Dis. 2015 Sep 15;61(6):950-9

Scand J Immunol. 2021 May;93(5):e13010

Science. 2016 Apr 22;352(6284):aaf1098

Cited by 148 citations (total)

Journal Article Systematic Review

Effectiveness of Bacille Calmette-Guerin vaccination policies in reducing infection and mortality of COVID-19: a systematic review.

Electronic publication date November 9, 2022

Search for publications in this journal Glob Health Res Policy

Joseph Christian Obnial [...] Elaine Cunanan et al.

BACKGROUND

COVID-19 vaccination has been advocated as the most effective way to curb the pandemic. But with its inequitable distribution and...

Journal Article Meta-Analysis Systematic Review Research Support, U.S. Gov't, P.H.S. Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis.

Electronic publication date August 17, 2022

Search for publications in this journal Lancet Glob Health

Leonardo Martinez [...] Jason R Andrews et al.

BACKGROUND

BCG vaccines are given to more than 100 million children every year, but there is considerable debate regarding the effectiveness...

Conflict of interest statement

Declaration of interests SHEK is coinventor of the tuberculosis vaccine VPM1002 and coholder of a patent licensed to Serum Institute of India, Pune, India. MGN is coholder of patents on trained immunity licensed to Trained Therapeutix Discovery. CL reports personal fees from Chiesi, Gilead, Janssen, Novartis, Oxford Immunotec, and Insmed, outside of the submitted work. All other authors declare no competing interests.

MeSH

Specialties

Substances

Copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.